Form 4: Charles River Laboratories Executive Reports Routine Tax-Related Stock Dispositions

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories, reported the disposition of 640 shares of common stock over three days in May 2025, primarily for tax withholding purposes.

Summary

• Birgit Girshick, the Corporate Executive VP & COO of Charles River Laboratories International, Inc. (CRL), filed a Form 4 reporting changes in her beneficial ownership of company common stock.
• On May 26, 2025, Ms. Girshick disposed of 281 shares of common stock at a price of $136.73 per share.
• On May 27, 2025, an additional 242 shares of common stock were disposed of at $136.73 per share.
• On May 28, 2025, a further 117 shares of common stock were disposed of at $138.65 per share.
• All reported transactions (totaling 640 shares) were marked with transaction code 'F', indicating a disposition to cover tax withholding obligations.
• Following these transactions, Ms. Girshick beneficially owned 53,988 shares of Charles River Laboratories common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are routine, non-discretionary dispositions for tax purposes, which is a common occurrence for executives receiving equity compensation. It does not reflect a change in the executive's confidence or the company's operational performance.

Positives

• The dispositions are non-discretionary and for tax withholding purposes, which is a routine part of executive compensation and does not indicate a lack of confidence in the company by the executive.
• The executive continues to hold a substantial number of shares (53,988 shares), aligning her interests with shareholders.

Negatives

• No negative operational or financial implications are indicated by this routine insider transaction.

Risks

• This Form 4 filing does not introduce new risks to the company's operations or financial health. The reported transactions are routine administrative events related to executive compensation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is specific to an insider transaction at Charles River Laboratories and does not provide broader insights into industry trends or competitive dynamics. Such filings are routine disclosures for publicly traded companies.

Stakeholder Impact

• Shareholders: Minimal impact, as these are routine tax-related dispositions and do not signal a change in the executive's long-term commitment or the company's fundamentals.
• Employees: No direct impact indicated by this filing.
• Customers: No direct impact indicated by this filing.
• Suppliers: No direct impact indicated by this filing.
• Creditors: No direct impact indicated by this filing.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Executive Compensation, Birgit Girshick